These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 33046132)

  • 21. [Rare diseases and their patient organization: the Hungarian Federation of People with Rare and Congenital Diseases].
    Pogány G
    Orv Hetil; 2014 Mar; 155(9):329-33. PubMed ID: 24566696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [FINANCING OF MEDICINES FOR TREATMENT OF RARE DISEASES OF THE NERVOUS SYSTEM. ORPHAN DRUGS IN RARE NEUROLOGICAL DISEASES].
    Szegedi Márta ; Kosztolányi G; Boncz I; Molnár MJ
    Ideggyogy Sz; 2016 Jan; 69(1-2):37-45. PubMed ID: 26987239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.
    Stockklausner C; Lampert A; Hoffmann GF; Ries M
    Oncologist; 2016 Apr; 21(4):487-93. PubMed ID: 27022038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of academic institutions in the development of drugs for rare and neglected diseases.
    Coles LD; Cloyd JC
    Clin Pharmacol Ther; 2012 Aug; 92(2):193-202. PubMed ID: 22760003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A proposed definition of rare diseases for China: from the perspective of return on investment in new orphan drugs.
    Cui Y; Han J
    Orphanet J Rare Dis; 2015 Mar; 10():28. PubMed ID: 25757391
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical trials of orphan drugs in China over the decade 2012-2022: Opportunities and challenges.
    Wu X; Xu W; Yu M; Zhang F; Wang H
    Pharmacol Res; 2022 Aug; 182():106349. PubMed ID: 35835367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Legal assessment of current situation on orphan patients in Lithuania.
    Spokiene I
    Medicina (Kaunas); 2008; 44(8):571-6. PubMed ID: 18791333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preparing for the Future of Rare Diseases.
    Groft SC; Posada de la Paz M
    Adv Exp Med Biol; 2017; 1031():641-648. PubMed ID: 29214596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Developing treatments for inborn errors: incentives available to the clinician.
    Haffner ME
    Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Orphan drugs and orphan diseases].
    Campos-Castelló J
    Rev Neurol; 2001 Aug 1-15; 33(3):216-20. PubMed ID: 11588712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dealing with Uncertainty and Accounting for Social Value Judgments in Assessments of Orphan Drugs: Evidence from Four European Countries.
    Nicod E; Berg Brigham K; Durand-Zaleski I; Kanavos P
    Value Health; 2017; 20(7):919-926. PubMed ID: 28712621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Orphan drug policy analysis in China.
    Liu M; Lu Y; Li J; Zhang Y; Zhang S; Liu Y
    Front Pharmacol; 2024; 15():1278710. PubMed ID: 38939834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rare Diseases: Joining Mainstream Research and Treatment Based on Reliable Epidemiological Data.
    Groft SC; Posada de la Paz M
    Adv Exp Med Biol; 2017; 1031():3-21. PubMed ID: 29214563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Shift of focus in the financing of Hungarian drugs. Reimbursement for orphan drugs for treating rare diseases: financing of enzyme replacement therapy in Hungary].
    Szegedi M; Molnár MJ; Boncz I; Kosztolányi G
    Orv Hetil; 2014 Nov; 155(44):1735-41. PubMed ID: 25344850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Orphan Drugs in Oncology.
    Korchagina D; Jaroslawski S; Jadot G; Toumi M
    Recent Results Cancer Res; 2019; 213():109-142. PubMed ID: 30543010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drugs for rare disorders.
    Cremers S; Aronson JK
    Br J Clin Pharmacol; 2017 Aug; 83(8):1607-1613. PubMed ID: 28653488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Delayed access to treatments for rare diseases: who's to blame?
    Feltmate K; Janiszewski PM; Gingerich S; Cloutier M
    Respirology; 2015 Apr; 20(3):361-9. PubMed ID: 25722183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exploring patient and family involvement in the lifecycle of an orphan drug: a scoping review.
    Young A; Menon D; Street J; Al-Hertani W; Stafinski T
    Orphanet J Rare Dis; 2017 Dec; 12(1):188. PubMed ID: 29273068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Catastrophic expenditure and impoverishment of patients affected by 7 rare diseases in China.
    Xin XX; Guan XD; Shi LW
    Orphanet J Rare Dis; 2016 Jun; 11(1):74. PubMed ID: 27266878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.